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Abstract
Background: Clear-cell Renal Cell Carcinoma (ccRCC) is the most- prevalent, chemotherapy resistant and lethal
adult kidney cancer. There is a need for novel diagnostic and prognostic biomarkers for ccRCC, due to its
heterogeneous molecular profiles and asymptomatic early stage. This study aims to develop classification
models to distinguish early stage and late stage of ccRCC based on gene expression profiles. We employed
supervised learning algorithms- J48, Random Forest, SMO and Naïve Bayes; with enriched model learning by fast
correlation based feature selection to develop classification models trained on sequencing based gene
expression data of RNAseq experiments, obtained from The Cancer Genome Atlas.
Results: Different models developed in the study were evaluated on the basis of 10 fold cross validations and
independent dataset testing. Random Forest based prediction model performed best amongst the models developed
in the study, with a sensitivity of 89%, accuracy of 77% and area under Receivers Operating Curve of 0.8.
Conclusions: We anticipate that the prioritized subset of 62 genes and prediction models developed in this study
will aid experimental oncologists to expedite understanding of the molecular mechanisms of stage progression
and discovery of prognostic factors for ccRCC tumors.
Background
Renal cell carcinoma is a common adult kidney cancer,
accounting for 2-3% of all new cancer cases diagnosed
worldwide [1]. Detection of renal cell carcinoma at an
early stage is difficult and generally diagnosed incidentally
[2]. Most cases can be treated effectively only if detected
timely, increasing the survival rates of patients [3]. The
clear-cell Renal Cell Carcinoma (ccRCC) is the most
common subtype of the renal cell carcinoma, character-
ized by clear cell morphology of the cytoplasm [4]. So
far, early stage diagnosis is difficult due to the molecular
complexity and divergent clinical behavior of ccRCC
patients [5]. Hence, there is an urgent need to determine
candidate biomarkers for diagnosis and/or prognosis for
stage specific distinction in ccRCC.
Advancements in high throughput technologies like
Next Generation Sequencing have opened novel avenues
in cancer research with renewed emphasis on diagnosis,
prognosis and therapeutics. The launch of large scale
comprehensive multi-node programs like International
Cancer Genomic consortium [ICGC] (http://icgc.org/) and
The Cancer Genome Atlas [TCGA] (http://cancergenome.
nih.gov/) enables systematic studies on genomic, epige-
nomic and transcriptomic levels for different cancer types
that hold clinical and societal importance globally [6].
These projects are making data available to researchers in
different levels 1, 2, 3, 4 (i.e. raw, processed, interpreted
* Correspondence: dinesh@icgeb.res.in
Bioinformatics Laboratory, Structural and Computational Biology Group,
International Centre for Genetic Engineering and Biotechnology (ICGEB),
Aruna Asaf Ali Marg, New Delhi, India
Jagga and Gupta BMC Proceedings 2014, 8(Suppl 6):S2
http://www.biomedcentral.com/1753-6561/8/S6/S2
© 2014 Jagga and Gupta; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and summarized respectively) enabling genome informed
personalized cancer medicine research [7,8].
Along with advances and affordability of high through-
put technologies and data, progress is also being made
towards personalized and predictive medicine for clinical
management of cancer patients. In order to analyze
diverse and multidimensional cancer related data, machine
learning techniques are being extensively applied for
cancer prognosis as well as diagnosis [9,10].
In ccRCC, clinical tumor staging by TNM staging
system is used - as prognostic factor; determines treatment
regimen of patient; confirmed to guide the surveillance
protocols and to assess risk of metastatic renal cell
carcinoma [3,11-13]. Although tumor stage being an effec-
tive prognostic factor, to our knowledge there has been no
systematic studies characterizing gene expression data for
tumor stage progression. Thereby, we hypothesized that
identifying gene expression signature that correlates with
clinical tumor stage progression might lead to discovery of
a panel of prognostic molecular signatures for ccRCC
tumors.
In this study, we have developed prediction models to
discriminate clinical tumor stages- early stage (I, II) and
late stage (III, IV) of ccRCC. The prediction models are
trained on gene expression data of RNAseq experiments
from TCGA by implementing state-of-art supervised
machine learning algorithms. The gene expression signa-
tures identified by feature selection approach, which
enriched classifier training, helped us to efficiently classify
the tumors based on their clinical tumor stage. Further,
we found that amongst the implemented machine learn-
ing techniques, predictive models based on Random
Forest algorithm performed the best with accuracy of
76.84% on independent data test, area under Receiver
Operating Characteristic Curve (auROC) of 0.778.
Methods
The overall methodology followed in the article is
summarized in Figure 1.
Data mining
The dataset for this study was downloaded from TCGA
data portal (https://tcga-data.nci.nih.gov/tcga/tcga-
Home2.jsp). The Level 3 RNAseq expression dataset
from cancer type KIRC i.e. Kidney Renal clear cell carci-
noma on Illumina HiSeq 2000 RNA sequencing plat-
form was obtained from TCGA data portal [14]. The
RNAseq expression data was available for 475 tumor
samples. Each patient gene expression profile consists of
gene expression data for 20,534 genes. Only tumor sam-
ples were taken into account in the study. The clinical
information for selected subjects was retrieved from the
“clinical Biotab” section of the data matrix based on the
BCR (Biospecimen Core Resource) IDs of the patients.
We generated a gene expression data matrix in Comma
Separated Value (CSV) file format from the data retrieved
from the TCGA data portal, with 20,534 genes as column
labels and 475 patients BCR ids as row labels. This was
achieved using in-house shell scripts. The ‘Reads Per
Kilobase per Million’ i.e. RPKM values of the mapped
reads, retrieved as an estimate for gene expression, were
used as feature vectors for classifiers trainings. In order to
generate a study dataset, we marked class label of “Early
Stage” for patients with clinical tumor stage I & II, and
class labels of “Late Stage” for tumor stage III & IV.
Testing and Training dataset gene expression matrix
with 9756650 (20,534 × 475) data points was randomly
stratified and split into 80% training-cum-validation data-
set (Additional File 2) and 20% independent testing dataset
(Additional File 3) using a PERL script, developed in
house.
Machine learning
All the Machine learning steps including data pre-
processing, feature selection, generating classification
models and independent testing was performed on
Waikato Environment for Knowledge Analysis (WEKA)
version 3.7.9 [15].
Feature selection: For reducing the dimensionality in
feature space and improving instance to feature ratio for
better machine learning, we combined WEKA attribute
evaluator ‘SymmetricalUncertAttributeSetEval’ with
search method of ‘FCBFSearch’. The algorithm Fast
Correlation Based Feature (FCBF) selection utilizes pre-
dominant correlation to identify relevant features in high
dimensional datasets [16]. This feature selection method
is used in conjunction with evaluator ‘Symmetrical
Uncert Attribute Eval’, which selects subset of features
based on symmetrical uncertainty with respect to another
features [16,17].
We then analyzed this subset gene list for Gene Ontol-
ogy (GO)- biological process annotations with WebGestalt
(http://bioinfo.vanderbilt.edu/webgestalt/), a Web-based
Gene Set Analysis Toolkit [18]. We visualized the impact
of our candidate genes at genomic (mutation, copy
number alterations), transcriptomic (expression) and
protein levels (expression) in ccRCC TCGA dataset
through cBio Cancer Genomics Portal [19,20]. We also
estimated overall Kaplan-Meier Survival curve based on
cases with and without alteration in these genes using
cBio Cancer Genomics Portal.
Classification algorithms
We employed four different state-of-the-art supervised
machine learning algorithms (J48, Naïve Bayes, Sequential
minimal optimization and Random Forest) for generating
the classification models. J48 is the java based implemen-
tation decision tree learning algorithm C4.5 [21]. Naïve
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Bayes algorithm works on the assumption that all the fea-
tures are statistically independent and is based on Bayes
theorem [22]. Sequential Minimal Optimization (SMO)
algorithm is an implementation of Support Vector Classi-
fier [23,24]. Random Forest is randomly constructed
ensemble of independent decision trees [25].
Training-cum-validation: The four supervised machine
learning algorithms (J48, LibSVM, Naïve Bayes, and Ran-
dom Forest) were trained on the subset features from fea-
ture selection and further validated by 10 fold cross-
validation. The training models thus generated were com-
pared based on the accuracy and auROC. Random Forest
classifier was optimized for number of trees and the mod-
els were generated using number of trees as 1000.
Independent dataset test: Independent data testing is
recommended to exclude the “memory” effect or bias for
trained classification models [26]. So, we re-evaluated the
performance of best-trained and cross-validated model on
independent dataset.
Performance evaluation
In order to evaluate the generated prediction models we
employed various evaluation metrics recommended for
evaluating the classifier’s performances i.e. accuracy,
sensitivity or recall, specificity, Matthews Correlation
Coefficient (MCC), F-value and auROC [27,28]. The
auROC is area under curve and is evaluated for compar-
ing performance of several classifiers.
Figure 1 Schematic representation of the overall strategy used in the study. Data was downloaded from TCGA data portal. Gene
expression values of the tumors constituted the descriptor values. Class labels were derived from the clinical information given in the Biotab of
the TCGA data portal. Resulting data was processed to generate training/testing data files. Feature selection and generation of classification
models was performed on WEKA Workbench.
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Results
Gene expression data matrix
The RNAseq dataset for 475 clinically diagnosed ccRCC
patients were retrieved from TCGA data portal. The data-
set includes gene expression levels for 20,534 genes in
tumor tissue samples of the patients. Thus, we generated a
study dataset of gene expression data matrix of 20,534 ×
475, columns and rows respectively. The data characteris-
tics of patients whose gene expression values have been
used in this study are given as Additional File 1. Further,
the study dataset was divided into 80% training-cum-
validation and 20% independent testing dataset. The distri-
bution of patients across training and testing dataset by
clinical tumor stage is given in Table 1.
Feature selection
Feature selection performed on training-cum-validation
dataset of 219 early stage and 161 late stage instances
by fast correlation based feature selection largely
reduced the feature vectors space from 20,534 genes to
62 genes (see additional files: 4 for list of genes, 5 for
distribution plot of the expression values for all the
selected 62 genes). From the GO Slim Annotation of
subset genes, we identified “multicellular organismal
process” (29 genes), “response to stimulus” (28 genes),
“metabolic process” (26 genes) and “biological regula-
tion” (26 genes) as most frequent GO annotations for
Biological Processes (Additional file 6). Oncoprint of the
62 identified candidate gene list by feature selection
determined the alterations of genomic profiles in 83.6%
of ccRCC cases (Additional file 6). Further validation of
the relevance of selected gene features was achieved by
performing survival Kaplan-Meir estimate. The survival
estimate revealed that the median months survival in
cases with alterations is 73.17 months and cases without
alterations is 90.38 months (Additional File 6).
Training-cum-validation
We evaluated training models by 10 fold cross-validation
for the classifiers trained on the four supervised machine
learning algorithms- SMO, Random Forest, J48 and Naïve
Bayes. All the models were based on standard error base
classifiers. The performances of the generated prediction
models were compared on the basis of accuracy and
auROC values (Table 2). The classification accuracy of the
generated prediction models ranges from 67.6% for J48, to
79.7% for Random Forest; and auROC value ranges from
0.7 for J48 to 0.876 for Random Forest. Based on accuracy
and auROC, we inferred that Random Forest based predic-
tion model has outperformed other three machine learn-
ing algorithms implemented in the study.
Independent data testing
Furthermore, we evaluated our prediction models on an
independent dataset with 55 early stage patients and 40
late stage patients. The performances of the prediction
models were compared on the basis of standard
statistical measures- accuracy, sensitivity, specificity,
F-measure, and auROC (Table 3). We observed coher-
ence in the performance of the models between inde-
pendent data testing and 10 fold cross validation based
on auROC values.
We evaluated sensitivity and specificity plot to deter-
mine prediction model with low error rates i.e. high sensi-
tivity and specificity. Sensitivity of all the models was in
the range of 79-94%, with highest sensitivity of 93.56% for
Naïve Bayes. Specificity of the models varied in a wide
range with lowest of 39.0% for J48 and the highest of
60.98% for Random Forest (Figure 2). Although, Naïve
Bayes based model shows the highest sensitivity, the best
sensitivity-specificity trade-off was observed for Random
Forest Classifier with 88.89% sensitivity and 60.98%
specificity.
The prediction accuracies of all the four predictive mod-
els on independent dataset were- 62.11, 72.63, 76.84, 73.68
for J48, Naive Bayes, Random Forest and SMO respec-
tively (Table 3). F-measures of the models developed in
the study is between 0.7 to 0.82. It is notable that amongst
the four evaluated prediction models, the model based on
Random Forest displays highest accuracy and F-measure.
ROC plot is evaluated to characterize threshold inde-
pendent performance of the prediction models. The ROC
plot of the classifiers showing tradeoff between true posi-
tive rate and false positive rate in Figure 3 and auROC
values in Table 3 suggests that prediction models based
on Random Forest algorithm performed better than
Naïve Bayes, SMO and J48. The prediction models had
Table 1 Summary of Training and Testing dataset
statistics.
Class label Clinical status Training Testing
Early Stage Stage I 180 45
Early Stage Stage II 39 10
Late Stage Stage III 97 24
Late Stage Stage IV 64 16
380 95
Table 2 Performance of prediction models generated by




Naïve Bayes 77.8947 0.843
Random Forest 79.7368 0.876
SMO 76.0526 0.745
# auROC denotes area under Receivers Operating Characteristic curve. Highest
numerical value in each column is highlighted as bold letters.
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an auROC value of more than 0.5 i.e. better than random
predictions, assuring their robust performance.
Thus, on the basis of statistical evaluators used for
characterizing the performance of the prediction models,
classifiers were ranked in following order- Random
Forest, Naïve Bayes, SMO and J48.
Hence, Random Forest based prediction model is an effi-
cient classifer with 88.89% sensitivity, 76.84% accuracy and
auROC of 0.778 for classifying early stage and late stage of
the ccRCC tumors, using gene expression profiles.
Discussion
Predictive classification models in cancer biology are
employed with either of the 3 foci- predicting cancer
susceptibility, recurrence or survivability [9]. Previous
studies in ccRCC employs gene expression profiles to pre-
dict survival [29,30] and determine newer tumor subtypes
[31,32]. We have used gene expression profiles of ccRCC
stage specific tumor tissues to train supervised machine
learning algorithms, towards our goal to develop classifica-
tion models for early stage to late stage tumor progression
of ccRCC.
The TCGA gene expression data for ccRCC patients has
diverse representation of age, gender and tumor stage
(Additional File 1). The patients with localized tumors
(stage I and II) were class labeled as early stage whereas
patients with locally advanced disease (stage III) and meta-
static disease (stage IV) as late stage. The TCGA gene
expression profile data available for 475 tumor samples
and 20,534 genes had no significant batch effects [14] and
came with the “curse of dimensionality”. An efficient fast
filter feature selection method based on predominant
correlation (fast correlation based feature selection) largely
reduced the feature space from 20,534 genes to 62 gene
expression profiles.
To analyze the details of selected training set genes
used in development of prediction models for ccRCC,
we first performed GO annotations in which the corre-
sponding biological processes displayed very broad but
consistency with cancer hallmarks [33]. Secondly, the
oncoprint visualization of the selected subset genes
displayed alterations in all the genomic profiles in 83.6%
of the TCGA ccRCC cases. Thirdly, ccRCC cases with
alterations in the selected genes had better overall
Table 3 Performance of prediction models by standard
statistical evaluation parameters for independent testing
dataset.
Classifier Accuracy Sensitivity Specificity F-value auROC#
J48 62.11 79.63% 39.02% 0.704918 0.563
Naïve Bayes 72.63 93.56% 48.78% 0.790323 0.749
Random
Forest
76.84 88.89% 60.98% 0.813559 0.778
SMO 73.68 87.04% 56.10% 0.789916 0.716
# auROC denotes area under Receivers Operating Characteristic curve. Highest
numerical value in each column is highlighted as bold letters.
Table 4 Literature validation of the genes selected by
feature selection
Category Genes
Renal Cancer MAPK7, FGFR3, OASL, GUCY2D, GHRH
Other Renal Disorder NOZ2, APOL1
Cancer Progression in other
cancers
IRF7, FOXA1, GREB1L, TOB1, RTP3,
IER2, RORL
Biomarker in other cancers SHOX, HDGFL1, HUS1B, GNG7,
AP1M1
# Detailed information about the genes selected by feature selection can be
found in Additional File 4
Figure 2 Sensitivity - Specificity plots. The sensitivity - specificity
plot for the classifiers was analyzed to reveal optimal prediction of
the models. All the generated prediction models had higher
sensitivity than specificity. Random Forest based classifier was
ranked highest with optimal performance in sensitivity and
specificity.
Figure 3 ROC plot. Receivers Operating Characteristic curve (ROC)
plot all the four classifiers. Amongst all the prediction models,
Random Forest achieved the maximum value for area under
Receivers Operating Characteristic curve (auROC) closely followed by
Naïve Bayes and SMO. J48 had the least auROC. Scalar values of
auROC are given in Table 3.
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survival than cases without alteration in these genes.
Lastly, the literature mining of the selected genes
revealed that 42 out of 62 genes are already reported in
literature for its involvement in cancer progression or
detection, either ccRCC or any other type of cancer.
This indeed increased our confidence on the applicabil-
ity of 62 selected genes for development of prediction
model as well as the prioritized list to be analyzed for
therapeutic and prognostic potential in case of ccRCC.
We found that the prediction model based on Random
Forest algorithm is the best classifier followed by Naïve
Bayes and SMO, which performed reasonably better than
J48 based prediction model. The results demonstrate that
early stage and late stage ccRCC tumors can be classified
with high sensitivity using gene expression profiles. Our
observations re-emphasizes the fact that machine learning
based models will play important role in the developing
field of predictive and personalized medicine.
Our study also illustrates a new method for classification
in ccRCC, wherein tumor stage information can be
derived from the molecular features, instead of tumor size.
In future, availability of additional ccRCC tumor patients
and inclusion of more feature vectors like miRNA expres-
sions, protein expression and SNP profiling data could
further enhance the accuracy of the prediction models
given the fact that ccRCC tumors typically have heteroge-
neous molecular profiles. Though we tested the prediction
models on independent testing datasets of 95 patients, the
outcome of such models needs to be interpreted judi-
ciously before incorporation into a clinical set up. We
anticipate that the selected gene expression features and
the prediction models developed in this study would expe-
dite the challenge for discovering molecular prognosis
factors and stage progression molecular signatures in
ccRCC tumors.
Conclusion
An empirical approach has been employed in this study
to develop classification model for tumor stage progres-
sion in ccRCC based on gene expression profiles. We
have identified a subset of 62 genes by feature selection,
the expression profiles of which predominantly corre-
lates with tumor-stage of the patient given the heteroge-
neous data in terms of tumor stage, age group and
gender of the patient. We report that Random Forest
based prediction model accurately and reliably classifies
patient tumor stages. We anticipate that such prediction
models based on the molecular correlates could contri-
bute to the optimal management of patients in ccRCC.
Currently, the prediction models generated are available
upon request to the authors. To the best of our knowl-
edge, we are reporting the first prediction model to clas-
sify ccRCC tumor stage based on gene expression
profiles.
Additional material
Additional file 1: Data characteristics of ccRCC level 3 information
for TCGA patients for KIRC. This file consists of 2 figures - Gender
wise stage distribution of the TCGA patients; and Age distribution
of the patients. The figures are in a Portable Document Format (PDF)
and can be viewed with any standard PDF viewer.
Additional file 2: Training dataset. This file consists of Training
dataset used in this study. The file is in a Comma Separated Value
(CSV) format with 20,534 gene’s expression in RPKM in column and 380
patients as rows. The file is in CSV format.
Additional file 3: Testing dataset. This file consists of Testing
dataset used in this study. The file is in a Comma Separated Value
(CSV) format with 20,534 gene’s expression in RPKM in column and 95
patients as rows. The file is in CSV format.
Additional file 4: Gene symbols and gene names and literature
validation of the selected genes after feature selection. This file
consists of 62 genes selected by feature selection in the study and gene
names annotated by DAVID-gene name batch viewer (http://david.abcc.
ncifcrf.gov/). Literature validation of 42 out of 62 genes for involvement
in renal cancer, renal disease, including disease association for cancer
progression, & biomarkers in other cancers is given from literature and
Gene Cards (http://www.genecards.org/). The file is in .docx format and
can be viewed using any document viewer like Microsoft Word.
Additional file 5: Distribution plot of the expression values selected
62 genes. This file consists of expression value distribution plots
generated by Weka Explorer of final 62 genes for the class label “Early
Stage” and “Late Stage”. The file is in .docx format and can be viewed
using any document viewer like Microsoft Word.
Additional file 6: Analysis of the 62 selected genes for GO
annotations - Biological Process; Oncoprint and Overall Survival
Kaplan-Meier Estimate from cBioportal for Cancer Genomics. This
file consists of 3 figures - Bar chart of GO biological process categories of
the selected 62 genes; Screen Shot of Oncoprint for genomic alterations
in selected 62 genes in ccRCC cases in cBioPortal for Cancer Genomics
age distribution of the patients; and Survival Kaplan-Meier Estimate for
selected 62 genes in ccRCC cases in cBioPortal for Cancer Genomics. The
figures are in a Portable Document Format (PDF) and can be viewed
with any standard PDF viewer.
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